dann kamen am Freitag die News,wegen des Krebsmittels und der Orphandrugzulassung: Shares in Antisoma (ASM) rose 7.5p to 185.5p yesterday after the biotechnology company said its lead product for ovarian cancer has been awarded orphan drugs status by the European commission The Times 2.Juni
Antisoma drug gains EU orphan drug status
Shares of Antisoma , the British biopharmaceutical company focusing on cancer therapies, rose 3.9 percent to 185 pence on Friday after it said its lead product pemtumomab was granted European orphan drug statu.
The ovarian cancer drug, formerly known as Theragyn, thereby gains ten years of European market exclusivity once it's launche.
Orphan drug status is an incentive provided by regulators for treatments of rare or life-threatening diseases that might otherwise not be commercially viabl.
It is intended to allow a sufficient return to justify investment in the costly development of these drugs.